Alterations in the tumor suppressor phosphatase and tensin homolog (PTEN) occur in a substantial proportion of solid tumors. These events drive tumorigenesis and tumor progression. Given its central role as a downregulator of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, PTEN is deeply involved in cell growth, proliferation, and survival. This gene is also implicated in the modulation of the DNA damage response and in tumor immune microenvironment modeling. Despite the actionability of PTEN alterations, their role as biomarkers remains controversial in clinical practice. To date, there is still a substantial lack of validated guidelines and/or recommendations for PTEN testing. Here, we provide an update on the current state of knowledge on biologic and genetic alterations of PTEN across the most frequent solid tumors, as well as on their actual and/or possible clinical applications. We focus on possible tailored schemes for cancer patients’ clinical management, including risk assessment, diagnosis, prognostication, and treatment.

Pten alterations and their role in cancer management: Are we making headway on precision medicine? / N. Fusco, E. Sajjadi, K. Venetis, G. Gaudioso, G. Lopez, C. Corti, E. Guerini Rocco, C. Criscitiello, U. Malapelle, M. Invernizzi. - In: GENES. - ISSN 2073-4425. - 11:7(2020 Jul), pp. 719.1-719.19. [10.3390/genes11070719]

Pten alterations and their role in cancer management: Are we making headway on precision medicine?

N. Fusco
Primo
;
E. Sajjadi;K. Venetis;G. Gaudioso;G. Lopez;C. Corti;E. Guerini Rocco;C. Criscitiello;
2020

Abstract

Alterations in the tumor suppressor phosphatase and tensin homolog (PTEN) occur in a substantial proportion of solid tumors. These events drive tumorigenesis and tumor progression. Given its central role as a downregulator of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, PTEN is deeply involved in cell growth, proliferation, and survival. This gene is also implicated in the modulation of the DNA damage response and in tumor immune microenvironment modeling. Despite the actionability of PTEN alterations, their role as biomarkers remains controversial in clinical practice. To date, there is still a substantial lack of validated guidelines and/or recommendations for PTEN testing. Here, we provide an update on the current state of knowledge on biologic and genetic alterations of PTEN across the most frequent solid tumors, as well as on their actual and/or possible clinical applications. We focus on possible tailored schemes for cancer patients’ clinical management, including risk assessment, diagnosis, prognostication, and treatment.
Biomarker; Cancer; PI3K/Akt; Precision medicine; PTEN; Solid tumors; Tumor immune microenvironment; Tumor suppressor;
Settore MED/08 - Anatomia Patologica
Settore MED/06 - Oncologia Medica
lug-2020
28-giu-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
[2020] [Genes] PTEN review genes-11-00719 (1).pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.36 MB
Formato Adobe PDF
1.36 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/749867
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 73
  • ???jsp.display-item.citation.isi??? 66
social impact